Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antiandrogen therapy-M.D. Anderson Cancer Center-prostate cancer
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
antiandrogen therapy-M.D. Anderson Cancer Center-prostate cancer refers to a specific combination treatment regimen being evaluated in a Phase II clinical trial (NCT04947254) for patients with high-risk localized or locally advanced prostate cancer. The regimen consists of intensive androgen ablation therapy administered after definitive radiation therapy, with or without the addition of the PARP inhibitor niraparib. The androgen ablation component is defined as either abiraterone acetate plus prednisone combined with androgen deprivation therapy (ADT), or apalutamide combined with ADT. This therapeutic approach aims to achieve maximal suppression of the androgen signaling axis while simultaneously inhibiting DNA repair mechanisms to improve clinical outcomes in biomarker-selected patients.
- Brand names
- ZejulaZytigaErleada
- Other names
- Androgen Ablation TherapyAAP + ADTApa + ADTAndrogen Ablation Therapy with or without Niraparib
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on antiandrogen therapy-M.D. Anderson Cancer Center-prostate cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antiandrogen therapy-M.D. Anderson Cancer Center-prostate cancer.